>
Switch to:

Orgenesis Gross Margin %

: -21.30% (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Orgenesis's Gross Profit for the three months ended in Dec. 2021 was $-1.47 Mil. Orgenesis's Revenue for the three months ended in Dec. 2021 was $6.89 Mil. Therefore, Orgenesis's Gross Margin % for the quarter that ended in Dec. 2021 was -21.30%.


The historical rank and industry rank for Orgenesis's Gross Margin % or its related term are showing as below:

ORGS' s Gross Margin % Range Over the Past 10 Years
Min: -300.13   Med: -19.7   Max: 42.65
Current: 20.68


During the past 13 years, the highest Gross Margin % of Orgenesis was 42.65%. The lowest was -300.13%. And the median was -19.70%.

ORGS's Gross Margin % is ranked worse than
86.07% of 718 companies
in the Biotechnology industry
Industry Median: 61.23 vs ORGS: 20.68

Orgenesis had a gross margin of -21.30% for the quarter that ended in Dec. 2021 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Orgenesis was 0.00% per year.


Orgenesis Gross Margin % Historical Data

The historical data trend for Orgenesis's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.53 42.65 -211.93 -300.13 20.68

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.10 45.14 28.64 17.89 -21.30

Competitive Comparison

For the Biotechnology subindustry, Orgenesis's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Orgenesis Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Orgenesis's Gross Margin % falls into.



Orgenesis Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Orgenesis's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=7.3 / 35.502
=(Revenue - Cost of Goods Sold) / Revenue
=(35.502 - 28.16) / 35.502
=20.68 %

Orgenesis's Gross Margin for the quarter that ended in Dec. 2021 is calculated as


Gross Margin % (Q: Dec. 2021 )=Gross Profit (Q: Dec. 2021 ) / Revenue (Q: Dec. 2021 )
=-1.5 / 6.892
=(Revenue - Cost of Goods Sold) / Revenue
=(6.892 - 8.36) / 6.892
=-21.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Orgenesis  (NAS:ORGS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Orgenesis had a gross margin of -21.30% for the quarter that ended in Dec. 2021 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Orgenesis Gross Margin % Related Terms

Thank you for viewing the detailed overview of Orgenesis's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)